★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Corteva, Inc. (CTVA) Moat Analysis
Corteva, Inc.
CTVA · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Corteva has two agricultural-input businesses: Seed and Crop Protection. Seed has the stronger moat through protected germplasm and trait IP, including patents around the Enlist system and monetization through out-licensing; farmers can nevertheless change brands annually and rival genetics remain strong. Crop Protection has a narrower, product-level IP advantage where newer chemistry is patent-, data- or know-how-protected, but generic entry and current price declines demonstrate weaker portfolio-wide pricing power. R&D spending, launch counts, productivity programs and cross-segment bundles were not treated as standalone moats without comparative evidence. Corteva remains on track for a fourth-quarter 2026 separation of Seed into SpinCo from the Crop Protection-focused New Corteva.
Primary segment
Seed
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
2 segments · 7 tags
Updated 2026-07-12
Segments
Seed
Commercial agricultural seeds and traits (corn, soybean, and other crops)
Revenue
61.6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Crop Protection
Crop protection (herbicides, insecticides, fungicides, seed treatments, and biologicals)
Revenue
38.4%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Moat Claims
Seed
Commercial agricultural seeds and traits (corn, soybean, and other crops)
Revenue share based on Q1 2026 segment net sales (Seed $3.023B of $4.905B). Operating profit share uses Q1 2026 segment operating EBITDA (Seed $1.034B of $1.468B). Source: Corteva Form 10-Q for quarter ended 2026-03-31: https://www.sec.gov/Archives/edgar/data/1755672/000175567226000010/ctva-20260331.htm
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Trait and germplasm IP can be monetized via out-licensing/royalties and helps defend differentiated seed performance.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Trait patent expirations and generic trait entry
- Regulatory restrictions on biotech traits or gene-editing
- Breakthrough competitor genetics/traits reduce differentiation
Leading indicators
- Out-licensing/royalty income trend
- Adoption rates of core trait platforms (e.g., Enlist system)
- Pipeline milestones and regulatory approvals for new traits
Counterarguments
- Large competitors also hold extensive trait IP; licensing can be reciprocal
- Farmers can switch seed brands annually if performance/price disappoints
Crop Protection
Crop protection (herbicides, insecticides, fungicides, seed treatments, and biologicals)
Revenue share based on Q1 2026 segment net sales (Crop Protection $1.882B of $4.905B). Operating profit share uses Q1 2026 segment operating EBITDA (Crop Protection $434m of $1.468B). Source: Corteva Form 10-Q for quarter ended 2026-03-31: https://www.sec.gov/Archives/edgar/data/1755672/000175567226000010/ctva-20260331.htm
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
A steady stream of differentiated new products (including biologicals) supports share and margin where products are protected by patents, regulatory data, and know-how.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and generic competition
- Regulatory bans/restrictions on specific active ingredients
- Pest/weed resistance reduces product efficacy
Leading indicators
- Sales mix from newer products vs legacy portfolio
- Gross margin and price realization by region
- Regulatory outcomes and re-registration timelines
Counterarguments
- Crop protection markets often commoditize quickly as generics enter
- Competitors can match portfolios via acquisition or in-licensing
Evidence
Corteva holds numerous additional patents covering its Enlist® traits or Enlist® weed control system.
The filing directly identifies patent coverage and says the portfolio supports continued licensing and protection of Enlist E3 traits.
"Seed continues to benefit from its strength in advanced genetics, growth in out-licensing ..."
Management explicitly ties Seed performance to advanced genetics and out-licensing (an IP monetization signal).
"The increase in price is due primarily to increased out-licensing income ..."
Out-licensing income suggests valuable proprietary traits/germplasm used by other market participants.
Volume improvement was driven by demand for new products and spinosyns
Current-period demand provides evidence that differentiated newer chemistry contributes commercially, while price declines show the limit of the advantage.
"Crop Protection YTD results driven by double-digit volume growth in new products and biologicals."
Explicit linkage of performance to new products/biologicals supports differentiated portfolio claims.
Risks & Indicators
Erosion risks
- Trait patent expirations and generic trait entry
- Regulatory restrictions on biotech traits or gene-editing
- Breakthrough competitor genetics/traits reduce differentiation
- Patent expiry and generic competition
- Regulatory bans/restrictions on specific active ingredients
- Pest/weed resistance reduces product efficacy
Leading indicators
- Out-licensing/royalty income trend
- Adoption rates of core trait platforms (e.g., Enlist system)
- Pipeline milestones and regulatory approvals for new traits
- Sales mix from newer products vs legacy portfolio
- Gross margin and price realization by region
- Regulatory outcomes and re-registration timelines
Research CTVA elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.